Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect and Safety of Semaglutide 7.2 mg Once-weekly in Participants With Obesity

Next Previous
Trial Profile

Effect and Safety of Semaglutide 7.2 mg Once-weekly in Participants With Obesity

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 24 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Semaglutide (Primary)
  • Indications Obesity
  • Focus Registrational; Therapeutic Use
  • Acronyms STEP UP
  • Sponsors Novo Nordisk

Most Recent Events

  • 15 Dec 2025 According to a Novo Nordisk Media Release, based on the results from this study the European Medicines Agencys (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion for a higher dose of Wegovy, bringing it a step closer to offering individuals with obesity in the EU.
  • 26 Nov 2025 According to the Novo Nordisk Media Release, based on results from this trial the company submitted sNDA to the U.S. Food and Drug Administration (FDA) for a higher dose of semaglutide injection 7.2 mg, to be used along with a reduced calorie diet and increased physical activity for chronic weight management in adults with obesity.Under the CNPV expedited program, review is expected within 1-2 months following the FDAs acceptance of the filing.
  • 20 Oct 2025 According to the Novo Nordisk Media Release, data will be presented at ObesityWeek from 4-7 November in Atlanta, US.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top